Anna Brown
LightNews LightNews
annajbrown.bsky.social
Anna Brown
@annajbrown.bsky.social
75 followers 160 following 6 posts
London-based reporter for Endpoints News | abrown@endpointsnews.com | Signal annabrown.04
Posts Replies Media Videos
Pinned
annajbrown.bsky.social
Anna Brown @annajbrown.bsky.social · Feb 19
Hello! Still in the process of moving over to Bluesky, for new friends: I write about biomanufacturing and supply chains over at @endpts.com -- feel free to reach out at abrown@endpointsnews.com for tips or just to say hi!

A taster of some manufacturing news today:

endpts.com/pfizers-manu...
Pfizer’s manufacturing arm at risk from Trump tariffs in Europe, Bourla says
Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable from President Donald Trump’s tariffs in Europe as the big pharma has
endpts.com
Reposted by Anna Brown
andrewedunn.bsky.social
Here's something new: our first-ever Post-Hoc Live happens tomorrow at noon ET

Watch @drewsnews.bsky.social, @maxbayer.bsky.social and @annajbrown.bsky.social talk pharma & tariffs — while live!

endpts.com/how-pharma-i...
How pharma is reacting to ‘Liberation Day’: Join us tomorrow for Post-Hoc Live!
Live stream podcast tomorrow at 12pm ET with Drew Armstrong, Max Bayer & Anna Brown discussing pharma industry's response to Trump administration tariffs, including lobbying & manufacturing changes.
endpts.com
April 29, 2025 at 6:49 PM
Reposted by Anna Brown
maxgelman.bsky.social
Johnson & Johnson CEO Joaquin Duato subtly but assertively criticized President Donald Trump's plans for pharmaceutical tariffs, saying tax policy is a better way to onshore US drug manufacturing.

endpts.com/jj-ceo-chide...
J&J's Duato says 'not tariffs, but tax policy' is best way to boost US manufacturing
The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, saying they are not an effective tool to onshore drug manufacturing to the US.
endpts.com
April 15, 2025 at 7:46 PM
annajbrown.bsky.social
While Trump has launched a 232 investigation to tax pharmaceuticals, he's simultaneously issued an executive order to lower US drug prices. See @zacharybrennan.bsky.social coverage on this at @endpts.com: endpts.com/trump-pledge...
Trump pledges his support for a change to the IRA long sought by drugmakers
Trump signs EO on drug pricing, supports PhRMA reforms for Medicare negotiations timeline, calls for Canadian drug imports, and includes 340B program changes for EpiPens and insulin.
endpts.com
April 16, 2025 at 8:53 AM
annajbrown.bsky.social
Pharma tariffs are likely to leave little room to hide for companies as the 232 investigation hits all the major parts of the supply chain: endpts.com/trumps-pharm...
Pharma tariffs could leave little room to hide with sweeping probe underway
A US trade probe into pharmaceuticals is underway. And it’s hitting many of the key aspects of the supply chain.
endpts.com
April 16, 2025 at 8:23 AM
annajbrown.bsky.social
Yesterday I wrote a piece for @endpts.com on what Trump's potential tariff rollout could look like for pharmaceuticals: endpts.com/pharma-tarif...

But CDMOs seem more concerned with the current FDA staff cutbacks delaying inspections: endpts.com/cdmos-antici...
Pharma tariffs: Here’s what a potential rollout could look like
Trump signals imminent pharma tariffs, with experts including Mollie Sitkowski of Faegre Drinker suggesting 25% levy possible. China's API exports to US could face major impact.
endpts.com
April 11, 2025 at 2:04 PM
Reposted by Anna Brown
lizessleywhyte.bsky.social
Former FDA Commissioner:
April 1, 2025 at 12:59 PM
Reposted by Anna Brown
endpts.com
🚨 Breaking: Firings swept across the FDA, gutting leadership and whole offices, as some staff found out their jobs were cut when they showed up to work on Tuesday.
endpts.com/firings-swee...
Breaking: Firings sweep across FDA, gutting leadership and whole offices
Mass firings and forced resignations swept through the FDA on Tuesday, as part of thousands of planned job cuts at federal health agencies being implemented by the Trump administration.
endpts.com
April 1, 2025 at 12:39 PM
annajbrown.bsky.social
Ahead of potential pharmaceutical tariffs next week, @maxbayer.bsky.social broke down what this could mean for the industry @endpts.com:

endpts.com/trump-pharma...
Three major questions on pharma tariffs Trump claims are on the way
Trump threatens pharma tariffs on foreign-made drugs, particularly targeting Ireland. Industry faces potential $63B annual tariff increase per PwC. Eli Lilly, J&J, AstraZeneca boost US investment.
endpts.com
March 25, 2025 at 9:55 AM
Reposted by Anna Brown
zacharybrennan.bsky.social
DOGE terminates lease on FDA pharma quality lab in St. Louis that employs about 70 scientists - unclear on their fate endpts.com/doge-shutter...
DOGE terminates lease on FDA quality lab in St. Louis, and 29 other sites
DOGE says that it has terminated the leases of 30 FDA offices and buildings, including a 52,000 square-foot St. Louis-based lab that operates under the FDA's Office of Pharmaceutical Quality.
endpts.com
March 4, 2025 at 5:13 PM
annajbrown.bsky.social
Endpoints weekly manufacturing newsletter's out today, leading with our story on Lilly's $27 billion manufacturing push in the US from @zacharybrennan.bsky.social

endpts.com/lilly-says-i...
Updated: Lilly joins Trump administration to announce $27B manufacturing commitment
WASHINGTON — Eli Lilly touted a huge new US manufacturing investment at an event on Wednesday, trotting out the news with a member of President Donald Trump’s cabinet as part of ...
endpts.com
February 27, 2025 at 5:24 PM
Reposted by Anna Brown
zacharybrennan.bsky.social
We are too! DM me or find me on Signal at zacharybrennan.20
February 26, 2025 at 6:21 PM
Reposted by Anna Brown
zacharybrennan.bsky.social
Some of the user fee-funded staff at FDA were reinstated on Monday, after being laid off about a week ago for dubious reasons. 183 of the 230 staffers initially let go were supported by the user fee program endpts.com/some-fda-med...
Some FDA medical device staff reinstated just days after receiving pink slips
Some of the more than 200 staffers laid off at the FDA's Center for Devices and Radiological Health (CDRH) returned to work Monday, about a week after hearing their roles would be cut, several device ...
endpts.com
February 24, 2025 at 8:16 PM
Reposted by Anna Brown
theguardian.com
Amanda Pritchard quits as NHS England chief executive in shock move
Amanda Pritchard quits as NHS England chief executive in shock move
Exclusive: Departure follows meetings with Wes Streeting and unusual criticism from two Commons committees Amanda Pritchard is standing down as chief executive of NHS England, in a development that will shock the health service. Her departure from the…
www.theguardian.com
February 25, 2025 at 10:14 AM
Reposted by Anna Brown
sherylnyt.bsky.social
Young scientists, doctors, and public health professionals who earned prestigious federal fellowships are getting the axe from Trump. Is this how to plan for the next pandemic?

“We owe them a debt of gratitude, not a pink slip,” former agency heads said.

www.nytimes.com/2025/02/18/u...
Trump Cuts Target Next Generation of Scientists and Public Health Leaders
A core group of so-called disease detectives, who track outbreaks, was apparently spared. But other young researchers are out of jobs.
www.nytimes.com
February 18, 2025 at 12:56 PM
Reposted by Anna Brown
andrewedunn.bsky.social
Pfizer CEO Bourla: “Do I think we can convince them to do something bold in vaccines with Kennedy in HHS? Probably not. But do I think that we can convince them to do something very bold for cancer or for cardiovascular diseases with Kennedy in HHS? Absolutely I do.”
endpts.com/pfizer-ceo-s...
Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma
Over 500 pharma executives, lobbyists, consultants and other industry members gathered a couple miles from the White House on Tuesday, as top industry leaders took the stage and tried out some new mes...
endpts.com
February 19, 2025 at 3:57 PM
Reposted by Anna Brown
chrisgeidner.bsky.social
BREAKING: Nonprofits sue over Trump's anti-diversity, anti-trans executive orders, alleging they violate the First Amendment & equal protection guarantees, are void for vagueness, exceed the president's authority, & violate the Administrative Procedure Act. storage.courtlistener.com/recap/gov.us...
The terms of the Executive Orders are extraordinarily vague and could prohibit Plaintiffs from engaging in any targeted effort to help a specific group of people facing unfair disadvantages. The Executive Orders equate banned "DEIA" with any equity-related work— potentially including work that is specifically authorized or required by civil rights laws-and explicitly prohibit references to "DEI and DEIA principles, under whatever name they may appear." Without any discernible standards or criteria of what is and what is not "dangerous, demeaning," "immoral," and "illegal" DEIA,' as understood by this Administration, the future of Plaintiffs' fiscal viability and programming are subject to the unfettered discretion of an Administration that has made clear its predisposition against any speech or action that advances equal opportunity for historically marginalized groups, including people of color, women, LGBTQ people, and/or people with disabilities. Such vague terms without sufficient standards or criteria deprive Plaintiffs of their due process rights under the Fifth Amendment. 9. In addition to violating Plaintiffs' free speech and due process rights, the Executive Orders have a clear discriminatory purpose in violation of equal protection: to malign the targeted communities; to undermine and dismantle a wide spectrum of policies, programs, and activities intended to help historically marginalized, underserved, and under-resourced groups; and to erase transgender people from public life. REQUEST FOR RELIEF Plaintiffs respectfully request that the Court grant the following relief: A. A declaration pursuant to 28 U.S.C. § 2201 that Executive Order Nos. 14151, 14168, and 14173 and any implementing agency actions are unlawful, unconstitutional, and invalid. A permanent injunction enjoining Defendants, their officials, agents, employees, assigns, and all persons acting in concert or participating with them from implementing or enforcing Executive Order Nos. 14151, 14168, and 14173, including without limitation the promulgation of any rules or regulations, in any manner against Plaintiffs by way of contract, subcontract, purchase order, grant, or sub-grant. C. A permanent injunction mandating that Defendants permanently rescind all agency-wide directives implementing and effectuating Executive Order Nos. 14151, 14168, and 14173 against Plaintiffs that were issued prior to this injunction. D. A permanent injunction mandating that Defendants unwind, rescind, strike, modify, or otherwise rectify contracts, subcontracts, agreements, and/or any other such binding documents entered into with Plaintiffs, in which terms, clauses, or provisions have been inserted pursuant to or in furtherance of Executive Order Nos. 14151, 14168, and 14173.
February 19, 2025 at 5:05 PM
annajbrown.bsky.social
Hello! Still in the process of moving over to Bluesky, for new friends: I write about biomanufacturing and supply chains over at @endpts.com -- feel free to reach out at abrown@endpointsnews.com for tips or just to say hi!

A taster of some manufacturing news today:

endpts.com/pfizers-manu...
Pfizer’s manufacturing arm at risk from Trump tariffs in Europe, Bourla says
Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable from President Donald Trump’s tariffs in Europe as the big pharma has
endpts.com
February 19, 2025 at 5:12 PM
Reposted by Anna Brown
gtconway.bsky.social
We’ve seen this movie before.
February 19, 2025 at 3:09 PM
Reposted by Anna Brown
endpts.com
Pfizer’s contract manufacturing arm operates 12 facilities in Europe. CEO Albert Bourla warned that the business could be vulnerable to tariffs on European imports proposed during Donald Trump’s presidency.
Pfizer’s manufacturing arm at risk from Trump tariffs in Europe, Bourla says
Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable from President Donald Trump’s tariffs in Europe as the big pharma has
endpts.com
February 19, 2025 at 2:18 PM